| Not Yet Recruiting | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas NCT07468136 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma NCT06108206 | Columbia University | N/A |
| Suspended | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumo NCT05934630 | Pediatric Brain Tumor Consortium | — |
| Recruiting | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma NCT05698524 | University of Nebraska | Phase 1 |
| Active Not Recruiting | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma an NCT04978727 | Children's Oncology Group | Phase 1 |
| Recruiting | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082 | Jazz Pharmaceuticals | Phase 1 |
| Completed | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas NCT04295759 | Pediatric Brain Tumor Consortium | Phase 1 |
| Recruiting | Implantable Microdevice In Primary Brain Tumors NCT04135807 | Oliver Jonas | EARLY_Phase 1 |
| Recruiting | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) G NCT04623931 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in P NCT03971734 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Active Not Recruiting | Pediatric Long-Term Follow-up and Rollover Study NCT03975829 | Novartis Pharmaceuticals | Phase 4 |
| Completed | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies fo NCT03434262 | St. Jude Children's Research Hospital | Phase 1 |
| Active Not Recruiting | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant NCT03180502 | NRG Oncology | Phase 2 |
| Completed | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 NCT02684058 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma NCT03353896 | University of Southern California | N/A |
| Completed | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children NCT03043391 | Istari Oncology, Inc. | Phase 1 |
| Completed | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma NCT03072134 | Northwestern University | Phase 1 |
| Completed | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas NCT02871843 | EpicentRx, Inc. | Phase 1 |
| Completed | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma NCT02101905 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors NCT02644291 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas NCT02238496 | Andrew B Lassman, MD | Phase 1 |
| Terminated | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma NCT02168270 | University of Nebraska | Phase 1 |
| Completed | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brai NCT01985256 | Tocagen Inc. | Phase 1 |
| Terminated | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas NCT01849952 | Dartmouth-Hitchcock Medical Center | — |
| Completed | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors NCT01975116 | Pediatric Brain Tumor Consortium | Phase 1 |
| Completed | Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II T NCT01847235 | Seoul National University Hospital | Phase 2 |
| Terminated | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas NCT01721577 | Rush University Medical Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma NCT01250470 | Roswell Park Cancer Institute | Phase 1 |
| Unknown | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma NCT01656980 | Shandong Lanjin Pharmaceuticals Co.,Ltd | Phase 3 |
| Unknown | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma NCT01637753 | Shandong Lanjin Pharmaceuticals Co.,Ltd | N/A |
| Completed | BIBF 1120 for Recurrent High-Grade Gliomas NCT01380782 | Patrick Y. Wen, MD | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Re NCT01470794 | Tocagen Inc. | Phase 1 |
| Completed | AZD8055 for Adults With Recurrent Gliomas NCT01316809 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas NCT01281982 | National Cancer Institute (NCI) | — |
| Completed | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Mal NCT01156584 | Tocagen Inc. | Phase 1 |
| Completed | Cellular Immunotherapy Study for Brain Cancer NCT01144247 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions NCT01082926 | City of Hope Medical Center | Phase 1 |
| Completed | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Fo NCT00995007 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma NCT00734864 | Annick Desjardins | Phase 1 |
| Completed | Sorafenib in Newly Diagnosed High Grade Glioma NCT00884416 | University Hospital, Geneva | Phase 1 |
| Terminated | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma NCT01095094 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas NCT00734682 | University of California, San Francisco | Phase 1 |
| Completed | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors NCT00667394 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patien NCT00645385 | Weill Medical College of Cornell University | — |
| Completed | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme NCT00390299 | Mayo Clinic | Phase 1 |
| Completed | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previo NCT00303849 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Completed | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma NCT00362570 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recu NCT00064779 | INSYS Therapeutics Inc | Phase 1 |
| Terminated | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas NCT00062504 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms NCT00004688 | Emory University | Phase 2 |
| No Longer Available | Expanded Access to ANG1005 for Individual Patients NCT02755987 | Angiochem Inc | — |